Investigation of the distribution of particles of drugs with the help of cascade impactor
BACKGROUND. Successful nebulization is a result of joint usage of nebulizer and medication, which equally define availability and disposition of the active substance. Amount of the substance delivered by different nebulizer systems may differ in more than 10 times.
OBJECTIVE. The aim of the study was to investigate the distribution of aerosol particles of drugs for inhalation manufactured by «Yuria-Pharm» under conditions of usage of Ulaizer Home.
MATERIALS AND METHODS. We investigated Ulaizer Home nebulizer and medications for inhalation (Decasan, Lorde hyal, Nebufluson, Nebutamol) with the help of new generation impactor (“Copley Scientific Limited”, Great Britain).
RESULTS AND DISCUSSION. Mass median aerodynamic diameter (MMAD) of Decasan particles was 4.878 µm, geometric standard deviation (GSD) – 1.72. MMAD of Lorde hyal particles was 3.194 µm, GSD – 1.556. Drop distribution for Nebutamol was alike the distribution for non-viscous aqueous solutions (MMAD – 5.363 µm, GSD – 1.924). For Nebufluson MMAD was 5.491 µm, GSD – 1.724.
CONCLUSIONS. The delivery of the inhaled drug to the required area of the respiratory system is a key to successful nebulization. It directly depends on the parameters of the aerosol. The distribution of particles of drugs manufactured by «Yuria-Pharm» in case of nebulization using Ulaizer Home allows to deliver the required amount of drug to the predefined parts of the respiratory system.
Price D., Chrystyn H., Kaplan A., Williams A.E. ABS34: could interchangeable use of dry powder inhaler compromise quality of care? An international study of physicians and pharmacists. Prim. Care Respir. J. 2006; 15: 194.
Gumeniuk M.I., Denysova O.V., Gumeniuk G.L. et al. Decamethoxin: nebulization therapy of infectious exacerbation of chronic bronchitis. Asthma and allergy. 2019; 3: 17-28.
Chew N.Y.K., Chan H.K. Pharmaceutical dry powder aerosols: emerging technologies. In: Swarbrick J., Boylan J. C. (Eds.). Encyclopedia of Pharmaceutical Technology. Marcel Dekker. New York, 2002.
Patel B., Gupta N., Ahsan F. Barriers that inhaled particles encounter. In: ISAM Textbook of Aerosol Medicine. Dhand R. (Ed.). International Society for Aerosols in Medicine, online publication, Werne, North Rhine-Westphalia, Germany. 2015: 707-727.
Newman S.P. Drug delivery to the lungs: challenges and opportunities. Ther. Deliv. 2017; 8 (8): 647‐661.
McCallion O.N.M., Taylor K. M.G., Thomas M., Taylor A. J. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm. Res. 1995; 12 (11): 1682-1688.
Everard M. L. Role of inhaler competence and contrivance in “diﬃcult asthma”. Paediatr. Respir. Rev. 2003; 4: 135-142.
Chandel A., Goyal A. K., Ghosh G., Rath G. Recent advances in aerosolised drug delivery. Biomedicine & Pharmacotherapy. 2019; 112: 108-601.
Hinds W. Aerosol technology: properties, behavior, and measurement of airborne particles. Wiley-Interscience, New York, 1982, 442 pp.
de Boer A. H., Hagedoorn P., Frijlink H. W. The choice of a compressor for the aerosolisation of tobramycin (TOBI®) with the PARI LC PLUS® reusable nebuliser. Int. J. Pharm. 2003; 268 (1-2): 59-69.
Lexmond A., Forbes B. Drug delivery devices for inhaled medicines. Handb. Exp. Pharmacol. 2017; 237: 265‐280.
Stein S.W., Thiel C.G. The history of therapeutic aerosols. J. Aerosol Med. Pulm. Drug Deliv. 2017; 30: 20-41.
Dobryanskyi DV, Gymeniuk GL, Dudka PF at al. Nebulized therapy – practical aspects. Аsthma and allergy. 2018; 3: 54-62.
Ibrahim M., Verma R., Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med. Devices. 2015; 8: 131-139.
Mashat M., Clark B.J., Assi K.H., Chrystyn H. In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems. Pulm. Pharmacol. Ther. 2016; 37: 37-42.
Lavorini F., Fontana G. A., Usmani O. S. New inhaler devices – the good, the bad and the ugly. Respiration. 2014; 88: 3-15.
Pitance L., Vecellio L., Leal T. et al. Delivery eﬃcacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations. J. Aerosol Med. Pulm. Drug Deliv. 2010; 23: 389-396.
Najlaha M., Parveenb I., Albed Alhnan M. et al. The effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisers. Int. J. Pharm. 2014; 4: 234-241.
Hatley R. H.M., Byrne S. M. Variability in delivered dose and respirable delivered dose from nebulizers: are current regulatory testing guidelines suﬃcient to produce meaningful information? Med. Devices. 2017; 10: 17-28.
Kesten S., Israel E., Li G. et al. Development of a novel digital breath-activated inhaler: initial particle size characterization and clinical testing. Pulm. Pharmacol. Ther. 2018; 53: 27-32.
Hua J., Zhanga R., Bengb H. et al. Effects of flow pattern, device and formulation on particle size distribution of nebulized aerosol. Int. J. Pharm. 2019; 560: 35-46.
Buttini F., Rossi I., Di Cuia M. et al. Combinations of colistin solutions and nebulizers from lung infection management in cystic fibrosis patients. Int. J. Pharm. 2016; 502: 242-248.
Dhand R., Dolovich M., Chipps B. et al. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012; 9: 58-72.
Olveira C., Mûnoz A., Domen A. Nebulized therapy. SEPAR Year. Arch. Bronconeu- mol. 2014; 50: 535-545.
Ari A. Jet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers for better clinical outcomes. Eurasian J. Pulmonol. 2014; 16: 1-7.
Ari A. Drug delivery interfaces: a way to optimize inhalation therapy in sponta- neously breathing children. World J. Clin. Pediatr. 2016; 5: 281-287.
Boe J., Dennis J.H., O’Driscoll B.R. European respiratory society guidelines on the use of nebulisers. Eur. Respir. J. 2001; 18: 228-242.
Finlay W.H., Stapleton K.W., Zuberbuhler P. Variations in predicted regional lung deposition of salbutamol sulphate between 19 nebulizer types. J. Aerosol Med. 1998; 11: 65-80.
Dolovich M. B. Assessing nebulizer performance. Respir. Care. 2002; 47: 1290-1301.
Buttini F., Rozou S., Rossi A. et al. The application of quality by design framework in the pharmaceutical development of dry powder inhalers. Eur. J. Pharm. Sci. 2018; 113: 64-76.
Ziegler J., Wacthel H. Comparison of cascade impactor and laser diffraction for particle size. J. Aerosol. Med. 2005; 18: 311-324.
Fink J.B. Aerosol drug therapy. In: Kacmarek R.M., Stoller J.K., Heuer A.J. (Eds.). Egan’s fundamentals of respiratory care. 10th ed. Elsevier; Mosby, St., Louis, MI, USA: 2012. pp. 844-886.
Adorni G., Seifert G., Buttini F. et al. Aerosolization performance of jet nebulizers and biopharmaceutical aspects. Pharmaceutics. 2019; 11 (8): 406.
Lavorini F., Buttini F., Usmani O.S. 100 years of drug delivery to the lungs. Respiratory care. 2018; 63 (3).
This work is licensed under a Creative Commons Attribution 4.0 International License.